drugset / Trial / NCT07446998
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary objective of this study is to assess the effect of enobosarm on total body weight
Timeline
- Start
- 2026-03-26
- Primary completion
- 2027-10
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enobosarm | Small molecule | 3 mg | Oral |
| Background | Semaglutide | Peptide | — | Subcutaneous |